Synovus Financial’s Amicus Therapeutics FOLD Stock Holding History

Synovus Financial’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-206	Closed	-$3K	–	950
2020 Q2	$3K	Hold	206	–	–	﹤0.01%	1390
2020 Q1	$2K	Hold	206	–	–	﹤0.01%	1941
2019 Q4	$2K	Hold	206	–	–	﹤0.01%	1418
2019 Q3	$2K	Hold	206	–	–	﹤0.01%	1385
2019 Q2	$3K	Hold	206	–	–	﹤0.01%	1288
2019 Q1	$3K	Hold	206	–	–	﹤0.01%	1299
2018 Q4	$2K	Hold	206	–	–	﹤0.01%	1313
2018 Q3	$2K	Buy	+206	New	+$2.88K	﹤0.01%	1328

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Synovus Financial's FOLD Position: Q3 2020 in Review

Synovus Financial sold out of Amicus Therapeutics (FOLD) in Q3 2020, closing a stake of 206 shares — an estimated $3K sold.

Synovus Financial first reported a position in FOLD in Q3 2018 and held it in 8 quarters. The position peaked at $3K in Q2 2020. 250 funds tracked by Wall St. Rank hold FOLD as of Q3 2020.

Synovus Financial reported no remaining Amicus Therapeutics position as of Q3 2020 after selling out during the quarter.
Synovus Financial sold 206 Amicus Therapeutics shares in Q3 2020, an estimated $3K.
Synovus Financial first reported a position in Amicus Therapeutics in Q3 2018 and held it in 8 quarters.
Synovus Financial's Amicus Therapeutics position peaked at $3K in Q2 2020.
250 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.